Articles tagged with Cancer Stem Cells
Cancer stem cells (CSCs) play a key role in malignant cancer progression, but the mechanism of their plasticity remains unknown. Researchers have identified DKK1 as a pivotal molecule that autonomously diminishes CSC population and promotes metastatic colonization.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
Researchers at Moffitt Cancer Center have identified ΔNp63 as a protein that contributes to lung cancer development by regulating stem cells and crucial elements known as enhancers. The study found that mice deficient for ΔNp63 in the lung developed fewer lung tumors and had fewer stem cells compared to control mice.
Researchers discovered a protein, syndecan-2, that helps identify and deploy blood stem cells for treatments. Transplanting only cells expressing syndecan-2 could make blood stem cell transplants more efficient and less toxic.
Researchers at UC Davis Health developed a new treatment that simultaneously blocks IL-6 and TNF cytokines, providing superior protection against acute graft-versus-host-disease severity and mortality. The dual-cytokine blockade approach did not impair beneficial graft-versus-tumor effects.
Researchers have developed new preclinical models to understand gastric cancer development and spread. Using these models, they identified Lgr5-expressing tumour cells as responsible for driving gastric cancer growth and spread, establishing them as a potential therapeutic target.
Scientists have identified a cascade of four proteins that activate the cancer-causing protein ∆Np63α. By inhibiting these proteins, cancer stem cells can be controlled, and tumor growth slowed. This breakthrough offers new therapeutic options for squamous cell carcinoma.
Cleveland Clinic researchers found that verubecestat, an Alzheimer's disease treatment, reduces glioblastoma progression by reprogramming tumor-associated macrophages into tumor-suppressing macrophages. This transformation leads to increased phagocytosis of tumor cells and reduced tumor growth.
The Lef1 gene is found to suppress the development and growth of colorectal cancer by restricting cancer stem cell niches. Blocking this gene leads to increased tumor stem cell niches and accelerated tumor growth.
Researchers found that blood stem cells, which are among the smallest cells in the body, lose their ability to perform their normal function — replenishing the body’s blood cells — as they grow larger. However, when the cells were restored to their usual size, they behaved normally again.
Researchers have discovered the molecular mechanisms behind stem cell rolling in blood vessels, a complex process that slows down cells using long tethers. The findings offer new insights into improving stem cell transplantations and developing treatments for metastasizing cancers.
Skeletal muscle secretes a molecule that regulates around 35% of liver functions, with the remaining basal functions independent of muscle activity. Ageing alters this communication, leading to non-optimal functions and accelerated ageing.
Researchers at McGill University identified proteins that drive cancer stem cells in brain tumours. Targeting the protein galectin1 may provide a more effective treatment for glioblastoma when combined with radiation therapy. The study found significant improvement in tumour response to radiation therapy, resulting in expanded lifespan.
Researchers have found that breast cancer stem cells accumulate near a tumor arteriole, which they call the arteriolar niche. This niche promotes cancer cell features and potential development through the LPA/PKD-1 signaling pathway.
A recent study has uncovered the evolutionary forces at play in the aging of the blood system and identified individuals at increased risk of blood cancer. The research provides a robust indicator for classifying patients with ARCH mutations, allowing for more frequent screening and early treatment.
A new study published in Blood Cancer Discovery reveals that children with acute myeloid leukemia (AML) who have more DNA changes in their blood stem cells are more likely to survive. The researchers hope that this finding can be used as a tool to identify high-risk patients and improve treatment outcomes.
A new study published in Nature reveals that a commonly used psychiatric drug can boost the fitness of healthy gut stem cells, making them more resistant to cancer. A clinical trial is now underway to investigate whether lithium can prevent bowel cancer in individuals with familial adenomatous polyposis (FAP).
A UCLA team discovered a molecule that allows cancer stem cells to bypass the immune system, leading to increased growth and spread of head and neck squamous cell cancers. Inhibiting this molecule has been shown to disrupt cancer progression and eliminate these stem cells.
Researchers found that aged bone marrow niches restrict the function of rejuvenated hematopoietic stem cells, which can lead to leukemia. The study suggests that addressing the influence of an aged niche is crucial for sustaining the function of rejuvenated HSCs.
Researchers have identified a pair of microRNAs that help maintain breast cancer stem cells and drive tumor growth. Targeting these microRNAs may improve the prognosis of patients with aggressive forms of breast cancer by making cancer stem cells more susceptible to chemotherapy.
Researchers at Hokkaido University developed a hydrogel that rapidly reprograms differentiated cancer cells into cancer stem cells within 24 hours. The study has significant implications for developing targeted anti-cancer therapies and personalized medicines by targeting cancer stem cells, which are resistant to current treatments.
Scientists have identified new biomarkers in exosomes produced by cancer stem cells, which could help diagnose and predict malignant melanoma. These biomarkers were found to be present in the blood of patients with different stages of the disease, distinguishing them from healthy individuals.
A new method called MutaSeq can distinguish cancer stem cells from healthy stem cells using single cell sequencing. This technology has the potential to identify drug targets that could eradicate leukemia at its source.
This review article highlights the complex crosstalk between cancer stem cells (CSCs) and tumor-associated macrophages (TAMs), two key players in cancer progression. CSCs have been identified as the drivers of cancer initiation and progression, while TAMs create a protective microenvironment for CSC development and dissemination.
Researchers have discovered that two anti-viral enzymes, APOBEC3C and ADAR1, fuel the transition from pre-cancer stem cells to leukemia stem cells. Inhibiting these enzymes with existing medications may help prevent cancer, including leukemia.
Researchers discovered that the cancer stem cells' ability to form tumors is regulated by a molecular switch called Mll1. Blocking this enzyme can specifically target cancer stem cells, offering hope for more effective treatments. Clinical trials are underway to evaluate the use of Mll1 inhibitors in head and neck tumors.
Scientists have identified a key gene mechanism controlling cellular aging and rejuvenation in mesenchymal stem cells. The GATA6/SHH/FOXP1 pathway regulates MSC aging and rejuvenation, offering insights into developing treatments for age-related diseases.
Researchers used genome-wide profiling to study the epigenetic landscape of human stem cells, revealing important information about gene regulation. They found differences in chromatin structures between long-term and short-term stem cells, which could improve understanding of cancer cell behavior and stem cell therapy.
Researchers at Duke University have discovered a mechanism by which mesenchymal stem cells (MSCs) modulate the inflammatory response, extending their beneficial effects even after being cleared from the system. The study sheds light on how MSCs suppress T cell activation and reprogram disease-fighting cells to promote healing.
Scientists have discovered that baking soda can reprogram T cells to resist cancer cells' immune-suppressive effects. The treatment has reversed the suppressive effects on T cells in 10 transplant recipients with relapsed AML.
Researchers have found a new way to make leukemic stem cells vulnerable by specifically dislodging them from their niches, allowing for potential treatment against chronic myeloid leukemia. The approach uses an RNA molecule complex to prevent the cancer stem cell's retention in its tumor-supporting niche.
Research finds that high androgen levels can cause intestinal stem cells to divide excessively and produce fewer mature epithelial cells, increasing the risk of tumor formation. The study's findings may have implications for treating or preventing colon cancers through androgen regulation.
A McGill-led study reveals that suppressing the OSMR gene can improve radiation therapy effectiveness and expand lifespan in preclinical mouse models. Glioblastoma's resistance to therapy is overcome by starving cancer stem cells with energy production halted.
A novel, rapid carcinogen detection method using stem cells has been developed by scientists at Okayama University. The method, which takes only one week to yield results, involves testing chemicals on healthy stem cells to see if they convert into cancerous stem cells.
Researchers at UCLA have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma by targeting BMI1 proteins. The study found that using an anti-PD1 immunotherapy drug in combination with PTC209 successfully stopped cancer growth, prevented reoccurrences, and eliminated cancer stem cells.
Researchers at Okayama University have developed a model showing how liver cancer stem cells are born from normal stem cells under specific environmental conditions. The study successfully established liver CSCs without genetic manipulation, providing a crucial tool for further research and potential targeted therapies.
Researchers discovered that cancer stem cells' ability to synthesise proteins is the essence of their pluripotency and contributes to unlimited tumour growth. By blocking this capacity, tumours can be halted in an irreversible manner.
The iPS87 cell line is characterized as a cancer-inducing, stem cell-like cell line that can be used to develop novel treatments for prostate cancer. After 8 transfers, the cultured cells lost their tumor-inducing capability and stem cell marker expression.
Researchers at Moffitt Cancer Center found that targeting histone deacetylase HDAC11 blocks cancer stem cell self-renewal and overcomes drug resistance in non-small cell lung cancer. The study suggests that HDAC11 inhibitors may be a potential therapeutic strategy for NSCLC.
Researchers have discovered that dental pulp stem cells promote neuronal growth in tissue regeneration and cancer progression, while also recruiting facial neurons. The findings open up new paths towards effective therapies against cancer using drugs that modify the communication between neurons and cancer stem cells.
A team of researchers has created a detailed cell atlas of an entire salivary gland tumor in a mouse model, revealing that the tumor is composed of various cell types, including cancer stem cells. The study uses single-cell RNA sequencing technologies to identify these cells, which make up less than one percent of the tumor population.
Researchers at MDC have found a weakness in the most common form of kidney cancer by identifying stem cells that depend on two critical biochemical signals. Blocking these signals hinders tumor growth in several laboratory models, suggesting a promising new approach to treating human patients.
Researchers have created a computer algorithm called CytoTRACE that can identify the most dangerous cancer cells by analyzing gene expression. The tool may help target cancer-causing genes and improve treatment outcomes for patients with aggressive forms of breast cancer.
A new study suggests that rare, harmful genetic mutations present in healthy donors' stem cells can be passed on to cancer patients, causing heart damage, graft-versus-host disease and new leukemias. The study analyzed DNA samples from 25 AML patients and their matching donors, revealing 44% of donors had at least one harmful mutation.
Researchers have developed a plant-derived compound, SVC112, that specifically targets head and neck cancer stem cells while sparing healthy cells. This selective approach yields better tumor control with reduced toxicity compared to existing FDA-approved treatments.
Researchers found that two genes, HNF4A and HNF4G, help burn dietary fat in intestinal stem cells, which may increase cancer risk on a high-fat diet. Altered stem cell functions can lead to colon cancer.
A new biomarker, plectin, has been identified in cancer stem cells, which govern cancer survival and spread. Plectin's translocation onto the cell surface is linked to tumor invasion and metastasis, making it a potential target for drug development.
A study published in Nature Cell Biology has identified a protein called CD9 that drives growth of pancreatic cancer and could be a target for new treatments. The researchers found that CD9 is present on the surface of cancer stem cells, which are a driving force behind cancer growth.
Enteric glial cells convert into tumor growth promoters when exposed to secretions from colon tumors, regulating important intestinal functions and interacting with cancer stem cells. The study identifies key molecules involved in this process and offers new potential targets for cancer therapies.
Researchers discovered that leukemia stem cells suppress NKG2D-L proteins, evading the immune system. By inhibiting PARP1, these cells can be recognized and eliminated by NK cells.
A study identified Glycerol-3-phosphate dehydrogenase 1 (GPD1) as a molecular marker specific to dormant glioma stem cells. GPD1-producing cells are resistant to chemotherapy and radiation, and their activation leads to tumor relapse.
A new study finds that cancer incidence increases uniformly with age, contradicting the traditional model of oncogenesis. The research suggests that selection pressure acting on healthy cells and cancer cells determines who gets cancer, with a shift in favor of cancer-causing mutations in older age.
A novel therapy with a dual mechanism of action has been shown to reactivate the anti-cancer alarm system, eliminating cancer stem cells and activating the immune system. Combining LIF-neutralizing antibodies with immunotherapy promotes tumor regression, triggers immune memory, and increases survival in animal models.
Researchers found cancer stem cells can change surface markers in response to environmental stressors, making targeted therapies less effective. The study's findings could lead to more optimized treatments by understanding how tumor cells adapt to their microenvironment.
Researchers from FEFU and international partners discover potential targets for glioblastoma multiforme treatment by studying proteins in the WNT signaling pathway. The findings could lead to improved antitumor therapy outcome through suppression of cancer stem cells, accelerating tumor growth rate.
Researchers at Tel Aviv University developed a novel biosensor that can isolate and target leukemic stem cells, the most malignant of all leukemic cells. The sensor uses genetic encoding to identify and characterize these cells, which have high regenerative potential and escape targeted therapies.
Cancer stem-cells are responsible for recurrence and drug resistance. MTHFD2, a mitochondrial metabolic enzyme, plays a critical role in maintaining CSCs by consuming AICAR, leading to depletion of the intracellular pool. Targeting MTHFD2 may eradicate tumors and prevent recurrence.
Researchers found the immune system plays a crucial role in maintaining healthy intestinal stem cells and preventing bowel cancer by enhancing DNA repair mechanisms. The study discovered that cells of the innate immune system can recognize genotoxic environmental factors, such as glucosinolates, and send signals to epithelial stem cell...
Researchers at Kanazawa University have discovered a critical signaling pathway that drives the proliferation of cancer stem cells in breast cancer. The pathway, involving Semaphorin 3 and MICAL3 proteins, is targeted by inhibiting these proteins to reduce breast-cancer stem-like cells.
Researchers discover ADAR1 enzyme promotes cancer cell resistance to treatment by hyper-mutating tumor suppressor RNAs. This enzyme may provide a molecular radar for early detection of malignancies and represent a new therapeutic target for preventing cancer cell resistance.